Tozinameran

Tozinameran is a mRNA vaccine developed by BioNTech in cooperation with Pfizer for the prevention of COVID-19. It is also known under the brand name Comirnaty and was the first COVID-19 vaccine to receive authorization for use in the United States and the European Union.

Development and Authorization[edit | edit source]

Tozinameran was developed using BioNTech's proprietary mRNA technology. The vaccine works by introducing a small piece of the SARS-CoV-2 virus's genetic code in order to trigger an immune response and build immunity to the virus.

The vaccine was authorized for emergency use by the FDA in the United States on December 11, 2020, and by the EMA in the European Union on December 21, 2020. It has since been authorized for use in many other countries around the world.

Efficacy and Safety[edit | edit source]

Clinical trials have shown that Tozinameran has an efficacy rate of approximately 95% in preventing COVID-19 infection. The vaccine has been found to be safe and well-tolerated in clinical trials, with the most common side effects being mild and temporary, such as pain at the injection site, fatigue, and headache.

Dosage and Administration[edit | edit source]

Tozinameran is administered as a two-dose series, with the second dose given three weeks after the first. The vaccine is injected into the muscle of the upper arm.

Storage and Handling[edit | edit source]

Tozinameran must be stored at ultra-low temperatures, between -80°C and -60°C, until it is ready to be used. Once thawed, the vaccine can be stored at refrigerator temperatures for up to five days.